| |
|
|
|
|
|
 |
| |
|
4¿þÀÌÁö¼Ó¼ººñ¾× 4-WAY 12HOUR NASAL DROP[Oxymetazoline HCl]
|
|
ÀϹÝÀǾàǰ | ºñ±Þ¿©
|
|
¼öÀÔÀǾàǰ
|
| |
 |
¾Ë¸²: |
µå·°ÀÎÆ÷¿¡¼´Â ÀǾàǰ ÀÎÅÍ³Ý ÆÇ¸Å¸¦ ÇÏÁö ¾Ê½À´Ï´Ù. |
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
À¯·áȸ¿ø °áÀç½Ã¿¡´Â º¸´Ù ´Ù¾çÇÑ ¾à¹°Á¤º¸¸¦
ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ½À´Ï´Ù.
À¯·áÁ¤º¸¸ñ·ÏÀº Àü¹®È¸¿øÀ¸·Î
·Î±×ÀÎ ÇϽøé È®ÀÎ °¡´ÉÇÕ´Ï´Ù.
|
|
|
 | Çã°¡Á¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
û±¸ÄÚµå(KDÄÚµå) ºñ±Þ¿©Á¡°ËÄÚµå »óÇÑ±Ý¾× |
ºñ±Þ¿©
[»óº´ÄÚµåÁ¶È¸]
[Áúº´ÄÚµåÁ¶È¸]
|
| ºü¸¥Á¶È¸ |
|
| Á¦Ç°¼º»ó |
¹«»ö~¹ÌȲ»öÀÇ ¸¼Àº ¾×Á¦ [Á¦ÇüÁ¤º¸ È®ÀÎ] |
| Æ÷À塤À¯Åë´ÜÀ§ |
0.4989mg/ml: 14.8ml, 1EA |
| È¿´ÉÈ¿°ú |
[ÀûÀÀÁõ º° °Ë»ö]
ºÎºñµ¿¿°, ¾Ë·¹¸£±â¼º ºñ¿°, ±Þ ¡¤¸¸¼º ºñ¿°, Ç÷°ü¿îµ¿¼º ºñ¿°
|
| ¿ë¹ý¿ë·® |
* Àý´ë ÀÓÀǺ¹¿ëÇÏÁö ¸¶½Ã°í ¹Ýµå½Ã ÀÇ»ç ¶Ç´Â ¾à»ç¿Í »ó´ãÇϽñ⠹ٶø´Ï´Ù.
[󹿾à¾î]
¼ºÀÎ ¹× 6¼¼ ÀÌ»óÀÇ ¼Ò¾Æ : 1ȸ 2~3¹æ¿ï 1ÀÏ 2ȸ ¾çÂÊ ºñ°¿¡ Åõ¿©ÇÑ´Ù. ¿¬·É, Áõ»ó¿¡ µû¶ó ÀûÀýÈ÷ Áõ°¨ÇÑ´Ù.
[Á¦Çüº°º¹¾àÁöµµ]
|
| ±Ý±â |
- ÀÌ ¾à ¼ººÐ(ƯÈ÷ ¿°Èº¥ÀßÄÚ´½)¿¡ °ú¹ÎÁõ ¹× ±× º´·ÂÀÌ Àִ ȯÀÚ
- 6¼¼ ¹Ì¸¸ÀÇ À¯¾Æ
- °ÇÁ¶¼º ºñ¿° ȯÀÚ
- ³ì³»Àå ȯÀÚ(ƯÈ÷ Æó¼â°¢ ³ì³»Àå)
- MAOÀúÇØÁ¦, Ç÷¾Ð »ó½ÂÁ¦¸¦ Åõ¿©ÁßÀΠȯÀÚ
- Àü¸³¼± ºñ´ë·Î ÀÎÇÑ ¹è´¢°ï¶õȯÀÚ
|
| ½ÅÁßÅõ¿© |
- °ü»óµ¿¸ÆÁúȯ ȯÀÚ
- °íÇ÷¾Ð ȯÀÚ
- °©»ó¼±±â´ÉÇ×ÁøÁõ ȯÀÚ
- ´ë»ç¼ºÁúȯ(´ç´¢º´ µî) ȯÀÚ
- Å©·Òģȼº¼¼Æ÷Á¾ ȯÀÚ
- ¼öÀ¯ºÎ
|
| ÀÌ»ó¹ÝÀÀ |
- ÄÚ:
¼Ò¼º°¨, ÀÚ»ó°¨, ºñÁ¡¸·È»ó, ¹ÝÀÀ¼º ÃæÇ÷ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
½ÉÇ÷°ü°è : ½É°èÇ×Áø, ºó¸Æ, Ç÷¾Ð»ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
ÁßÃ߽Űæ°è : Àçä±â, µÎÅë, ºÒ¸éÁõ, ÇÇ·Î, ºÒ¾È°¨ÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
Àå±â Åõ¿©¿¡ ÀÇÇÑ ¸¸¼º ºñÆó»öÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù.
|
| »óÈ£ÀÛ¿ë |
MAOÀúÇØÁ¦, »ïȯ°è Ç׿ì¿ï¾à°ú º´¿ëÅõ¿©½Ã Ç÷°ü¼öÃàÀÛ¿ëÀ¸·Î Ç÷¾Ð»ó½ÂÀÌ ³ªÅ¸³¯ ¼ö ÀÖ´Ù. |
| Related FDA Approved Drug |
±âÁØ ¼ººÐ: OXYMETAZOLINE HYDROCHLORIDEOCUCLEAR (OXYMETAZOLINE HYDROCHLORIDE)
VISINE L.R. (OXYMETAZOLINE HYDROCHLORIDE)
|
|
|
 | Á¤º¸¿ä¾à |
|
|
|
µå·°ÀÎÆ÷ ÀǾàǰ ¿ä¾à/»ó¼¼Á¤º¸
|
|
 | ÄÚµå ¹× ºÐ·ùÁ¤º¸ |
|
|
| |
|
 | Á¦Ç°Á¤º¸ |
|
|
|
|
 | º¹¾àÁ¤º¸ |
|
|
|
|
|
 | ½É»çÁ¤º¸ |
|
|
|
|
 | ÇмúÁ¤º¸ |
|
|
| Ç׸ñ |
³»¿ë |
| DUR (ÀǾàǰ»ç¿ëÆò°¡) |
º´¿ë±Ý±â :
°í½ÃµÈ º´¿ë±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[»óÈ£ÀÛ¿ë/º´¿ë±Ý±â°Ë»ö]
¿¬·É´ë±Ý±â :
°í½ÃµÈ ¿¬·É±Ý±â ³»¿ëÀº ¾ø½À´Ï´Ù.
[¿¬·É´ë±Ý±â»ó¼¼°Ë»ö]
|
| Mechanism of Action |
Oxymetazoline¿¡ ´ëÇÑ Mechanism_Of_Action Á¤º¸ Oxymetazoline is a direct acting sympathomimetic amine, which acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. It produces vasoconstriction, resulting in decreased conjunctival congestion in ophthalmic. In nasal it produces constriction, resulting in decreased blood flow and decreased nasal congestion.
|
| Pharmacology |
Oxymetazoline¿¡ ´ëÇÑ Pharmacology Á¤º¸ Oxymetazoline a adrenergic alpha-agonists, direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis.
|
| Protein Binding |
Oxymetazoline¿¡ ´ëÇÑ ´Ü¹é°áÇÕ Á¤º¸ Not Available
|
| Half-life |
Oxymetazoline¿¡ ´ëÇÑ ¹Ý°¨±â Á¤º¸ Not Available
|
| Absorption |
Oxymetazoline¿¡ ´ëÇÑ Absorption Á¤º¸ Not Available
|
| Pharmacokinetics |
Oxymetazoline HClÀÇ ¾à¹°µ¿·ÂÇÐÀÚ·á
- È¿°ú¹ßÇö½Ã°£ : ºñ°³» Åõ¿© : 5~10ºÐ À̳»
- È¿°úÁö¼Ó½Ã°£ : 5~6 ½Ã°£
- ´ë»ç : ¾Ë·ÁÁ® ÀÖÁö ¾ÊÀ½
|
| Biotransformation |
Oxymetazoline¿¡ ´ëÇÑ Biotransformation Á¤º¸ Not Available
|
| Toxicity |
Oxymetazoline¿¡ ´ëÇÑ Toxicity Á¤º¸ Not Available
|
| Drug Interactions |
Oxymetazoline¿¡ ´ëÇÑ Drug_Interactions Á¤º¸ Cisapride Increased risk of cardiotoxicity and arrhythmiasMesoridazine Increased risk of cardiotoxicity and arrhythmiasThioridazine Increased risk of cardiotoxicity and arrhythmiasDonepezil Possible antagonism of actionGalantamine Possible antagonism of actionRivastigmine Possible antagonism of actionPropranolol Propranolol increases the serum levels of cisapride
|
CYP450 Drug Interaction |
[CYP450 TableÁ÷Á¢Á¶È¸]
|
| Drug Target |
[Drug Target]
|
| Description |
Oxymetazoline¿¡ ´ëÇÑ Description Á¤º¸ A direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1251)
|
| Dosage Form |
Oxymetazoline¿¡ ´ëÇÑ Dosage_Form Á¤º¸ Liquid NasalSolution NasalSolution Respiratory (inhalation)Solution / drops OphthalmicSpray Nasal
|
| Drug Category |
Oxymetazoline¿¡ ´ëÇÑ Drug_Category Á¤º¸ Adrenergic alpha-AgonistsNasal DecongestantsSympathomimetics
|
| Smiles String Canonical |
Oxymetazoline¿¡ ´ëÇÑ Smiles_String_canonical Á¤º¸ CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
|
| Smiles String Isomeric |
Oxymetazoline¿¡ ´ëÇÑ Smiles_String_isomeric Á¤º¸ CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C
|
| InChI Identifier |
Oxymetazoline¿¡ ´ëÇÑ InChI_Identifier Á¤º¸ InChI=1/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)/f/h17H
|
| Chemical IUPAC Name |
Oxymetazoline¿¡ ´ëÇÑ Chemical_IUPAC_Name Á¤º¸ 6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol
|
|
|
 | »ç¿ëÀÚÄÁÅÙÃ÷ |
|
|
|
|
|
-
ÃÖ±ÙÁ¤º¸¼öÁ¤ÀÏ 2024-12-24
-
º» ¼öÁ¤ÀÏ Á¤º¸´Â Çã°¡Á¤º¸ ÀÌ¿ÜÀÇ ±âŸÁ¤º¸ ¼öÁ¤ÀÏÀ» ÀǹÌÇϹǷÎ, Çã°¡Á¤º¸¼öÁ¤ÀÏÀº º»¹®¿¡ Ç¥±âµÈ ³¯Â¥¸¦ ÂüÁ¶ÇϽñ⠹ٶø´Ï´Ù.
|
|
¾Ë¸² |
»ó¼¼Á¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×À» Åä´ë·Î ÀÛ¼ºµÇ¾úÀ¸¸ç ¿ä¾àÁ¤º¸´Â »ó¼¼Á¤º¸ ¹× ±âŸ¹®ÇåÀ» ±â¹ÝÀ¸·Î µå·°ÀÎÆ÷¿¡¼ ÆíÁýÇÑ ³»¿ëÀÔ´Ï´Ù. Á¦Ç°Çã°¡»çÇ×ÀÇ ¸ñÂ÷¿Í ´Ù¼Ò »óÀÌÇÒ ¼ö ÀÖ½À´Ï´Ù. |
|
°æ°í |
µå·°ÀÎÆ÷ ÀǾàÇмúÁ¤º¸´Â ½ÄǰÀǾàǰ¾ÈÀüóÀÇ Á¦Ç°Çã°¡»çÇ×, Çмú¹®Çå, Á¦¾àȸ»ç Á¦°øÁ¤º¸ µîÀ» ±Ù°Å·Î ÀÛ¼ºµÈ Âü°í Á¤º¸ÀÔ´Ï´Ù.
Á¤º¸ÀÇ Á¤È®¼ºÀ» À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸³ª ÆíÁý»óÀÇ ¿À·ù, Çã°¡»çÇ× º¯°æ, Ãß°¡ÀûÀÎ Çмú¿¬±¸ ¶Ç´Â Àӻ󿬱¸ ¹ßÇ¥ µîÀ¸·Î ÀÎÇØ ¹ß»ýÇÏ´Â ¹®Á¦¿¡ ´ëÇØ µå·°ÀÎÆ÷´Â
Ã¥ÀÓÀ» ÁöÁö ¾Ê½À´Ï´Ù. ÀÚ¼¼ÇÑ ³»¿ëÀº ¡°Ã¥ÀÓÀÇ ÇÑ°è ¹× ¹ýÀû°íÁö¡±¸¦ ÂüÁ¶ÇØ ÁֽʽÿÀ.
¹Ýµå½Ã Á¦Á¶¡¤¼öÀÔ»ç, ÆÇ¸Å»ç, ÀÇ»ç, ¾à»ç¿¡°Ô ÃÖÁ¾ÀûÀ¸·Î È®ÀÎÇϽñ⠹ٶø´Ï´Ù.
ÀüÈ: 02-3486-1061 ¤Ó À̸ÞÀÏ: webmaster@druginfo.co.kr
|
|
¾Æ·¡ÀÇ ³»¿ëÀ» Æ÷ÇÔÇÑ Àüü µ¥ÀÌÅ͸¦ º¸½Ã·Á¸é
¿©±â·Î À̵¿ÇϽñ⠹ٶø´Ï´Ù.
º´¿ë±Ý±â ¹× ƯÁ¤¿¬·É´ë ±Ý±â ¼ººÐ
|
|
|
|